P&G
27.3.2020 15:16:05 CET | Business Wire | Press release
Today the Procter & Gamble Company (NYSE:PG) announced donations totalling $10 million USD in personal health and hygiene, household products, sanitizers and financial support to help people in need, including families, elderly citizens and health professionals, enabling access to everyday essentials. As part of this effort, P&G is donating $1 million to support the International Federation of Red Cross and Red Crescent Societies’ (IFRC) COVID-19 appeal, as well as individual European Red Cross Red Crescent national societies’ efforts, to improve the lives of Europe’s vulnerable people across the continent during these challenging times.
Since the onset of the outbreak, P&G has been working with long-standing partner organizations to understand how to best support communities, relief agencies and those impacted by this global emergency. Today, we are taking three immediate actions to support urgent public needs.
Supporting vital health care services: We will donate an initial one million dollars to the IFRC and Red Cross Red Crescent National Societies to provide health care, medical supplies and hygiene education to vulnerable people across Europe.
IFRC Regional Director for Europe (ad interim), Elkhan Rahimov, said the donation would enable Red Cross and Red Crescent volunteers and staff across Europe to continue their vital and lifesaving work on the frontline of the COVID19 response.
“In these times of great emergency, this support will enable us to keep helping the most vulnerable in our society. Older people and immune compromised, those in quarantine and isolation, migrants and the homeless. We are truly appreciative of Procter and Gamble’s support,” Mr Rahimov said.
Improving lives at home with everyday essentials: Everyone at P&G is working diligently to maintain the production, distribution and availability of all our brands, not only for consumers but also for the comfort and confidence of the medical workers, emergency services and first responders who are on the frontline of the battle against COVID-19. We are also working with Red Cross and Red Crescent National Societies and local foodbanks, to deliver everyday cleaning, health and hygiene essentials to those who need it most. During these unprecedented times, our brands enable people to do the simple things – brush their teeth, wash their hair, shave, wear a clean shirt, change a baby diaper, keep homes and clothes clean – actions that can help restore a sense of normalcy and improve everyday life and wellbeing.
Providing hand and surface sanitizers: We are shifting manufacturing to help protect frontline workers. We recently started producing sanitizer in several P&G manufacturing sites in Europe, to ensure our people can continue operating safely and supporting hospitals, health authorities and relief organizations. We are building capacity to provide a minimum of 10,000 litres of hand sanitizer in 16 countries around Europe, enabling more than 3 million hand washes per week.
Loic Tassel, P&G President, Europe said, “In 30 years of working in the consumer goods industry, I have never experienced such challenging times impacting far more than businesses, but our neighbours, our communities – every facet of our lives. The P&G team is committed to doing everything possible to ensure the health and safety of all our employees, to continue to serve our consumers with essential products and services and to take meaningful action to help communities in need and those on the frontlines. Together, P&G and its organization partners are stepping up as a force for good in service to our communities.”.
We cannot predict how and when this crisis will end but we’re committed to be part of the solution. We have mobilized the full capabilities of P&G and our partners to help out in this time of need, and we will be there for our employees, consumers and communities — stepping up to be a force for good – however long it takes.
– ENDS –
Notes to the Editor
Visit https://www.pg.com/covid19 to learn how we’re stepping up to serve during the COVID-19 crisis.
About International Federation of Red Cross and Red Crescent Societies
About IFRC
IFRC is the world’s largest humanitarian network, comprising 192 National Red Cross and Red Crescent Societies working to save lives and promote dignity around the world.
www.ifrc.org - Facebook - Twitter - YouTube
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gain® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com/ for the latest news and information about P&G and its brands.
To learn more, follow us on Twitter , LinkedIn , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200327005286/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
